Please activate JavaScript!
Please install Adobe Flash Player, click here for download

GRK 1482 Jahrbuch 2011-2014

SENIOR PRINCIPAL INVESTIGATORS GRK Annual Report 2011-2014 | Page 21 Education / Degrees 1976 - 1981 Agrarbiologie, Universität Hohenheim, Germany 1978 Diploma 1985 Dr. rer. nat. ’summa cum laude’, Universität Hohenheim 1989 Habilitation and venia legendi for Zoophysiology, Universität Hohenheim Positions held 1985 - 1988 Post-doc, The Ohio State University, Columbus, Ohio, USA 1988 - 1992 Research Associate, Inst. Zoophysiology, Universität Hohenheim 1992 - 1994 Heissenberg Stipend, MPI for Physiological and Clinical Research, Bad Nauheim. Germany 1994 - 2002 Full Professor (C3), Department Physiology, School of Veterinary Medicine, Hannover 2002 to date Technische Universität München, Full Professor (C4), Lehrstuhl Humanbiologie. Research Interests and Achievements The group of Michael Scheman is working in the field of translational neu- rogastroenterology. The primary aim is to provide novel insights into neu- ral control mechanisms of gut functions in health and disease in order to facilitate translation of basic science to clinical management of patients with functional and inflammatory bowel diseases as well as autoimmune disorders. The group uses state of the art imaging techniques based on calcium and voltage sensitive dyes to monitor activity of neurons, smooth muscle, epithelial and immune cells in healthy and diseased human intes- tinal specimens. This is accompanied by measurements of muscle activity and epithelial secretion to study pathways involved in the multidirectional signaling between nerves, muscle, epithelium and immune cells. Recently, the group presented evidence that nerve sensitization may be one of the pathophysiological hallmarks of irritable bowel syndrome and identified proteases signaling through PAR1 receptors as key mediators responsible for enhanced nerve activation. The principle relevance of altered mucosa nerve interactions in symptom generation is currently pursued by studying nerve activating properties of mucosal biopsy supernatants from patients with irritable bowel syndrome, Morbus Crohn, ulcerative colitis, eosinophylic esophagitis and functional dysphagia. In this context, a neuropharmacolo- gical approach is used to identify new drugs targets. Prof. Dr. Michael Schemann Technische Universität München Human Biology (Chair) Liesel-Beckmann-Str. 4, D-85350 Freising-Weihenstephan Selected Publications Schemann M, Camilleri, M. Functions and imaging of mast cell and neural axis of the gut. Gastroenterology. 2013, 144:698-704. Schemann M, Kugler EM, Buhner S, Eastwood C, Donovan J, Jiang W, Grundy D. The mast cell degranulator compound 48/80 directly activates neurons. PLoS One. 2012, 7:e52104. Mueller K, Michel K, Krueger D, Demir IE, Ceyhan GO, Zeller F, Kreis ME, Schemann M. Activity of protease-activated receptors in the human submucous plexus. Gastroenterology. 2011, 141:2088-2097. Schemann M, Hafsi N, Michel K, Kober OI, Wollmann J, Li Q, Zeller F, Langer R, Lee K, Cellek S. The beta3-adrenoceptor agonist GW427353 (Solabegron) decreases excitability of human enteric neurons via release of somatostatin. Gastroenterology. 2010, 138:266-74. Buhner S, Li Q, Vignali S, Barbara G, De Giorgio R, Stanghellini V, Cremon C, Zeller F, Langer R, Daniel H, Michel K, Schemann M. Activation of humanentericneuronsbysupernatantsofcolonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology. 2009, 137: 1425-34. Research Goals Control of muscle, epithelial and immune cell functions by the enteric nervous sytem Neuropathology of functional and inflamm- atory bowel diseases Development of biomarkers to improve dia- gnosis and treatment of functional gut diseases. Neuropharmacology of the human enteric nervous system